THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials

Richard G. Langley; Arnon D. Cohen; Peter Foley; Christopher Em Griffiths; Mark Lebwohl; C. Leonardi; K.L. Winthrop; James Proulx; Scott T. Rottinghaus; Robert Wołk; John R. Thompson; Svitlana Tatulych; Lotus Mallbris; R. N. Swanson

doi:10.1136/annrheumdis-2016-eular.2394

Related publications

Letter2021

Development of clinical diagnostic criteria for chronic plaque psoriasis: an international e‐Delphi study

M. Abo‐Tabik, Rosa Parisi, Sarah Willis, Christopher Em Griffiths, Darren M. Ashcroft

Article2022

Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Clay Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Em Griffiths

Article2023

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher Em Griffiths

Article2023

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Clay Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Em Griffiths

Article2016

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Christopher Em Griffiths, Ronald Vender, Howard Sofen, Leon Kircik, Huaming Tan, Scott T. Rottinghaus, Mary Bachinsky, Lotus Mallbris, Carla Mamolo

THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials

Discussion(0)